gcc19cart
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2022 (NCT05319314)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19BINDING AGENT
CD19
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05875402 | N/A | Apr 1, 2023 | Qingdao University |
| NCT05319314 | Phase 1 | Aug 1, 2022 | Innovative Cellular Therapeutics Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovative Cellular Therapeutics Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Qingdao University | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1